Vnkpharma Ltd

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—6

1. General Information

Vnkpharma Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 13039770 . The registered office is 21 Ablett Street, London, SE16 3BL.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

Rendering of services

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.3. Intangible Fixed Assets and Amortisation - Goodwill

Goodwill is the difference between amounts paid on the acquisition of a business and the fair value of the separable net assets. It is amortised to profit and loss account over its estimated economic life of 20 years.

2.4. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Leasehold	No depreciation
Fixtures & Fittings	20 % Reducing balance

2.5. Leasing and Hire Purchase Contracts

A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership. All other leases are classified as operating leases. The rights of use and obligations under finance leases are initially recognised as assets and liabilities at amounts equal to the fair value of the leased assets or, if lower, the present value of the minimum lease payments. Minimum lease payments are apportioned between the finance charge and the reduction in the outstanding liability using the effective interest rate method. The finance charge is allocated to each period during the lease so as to produce a constant periodic rate of interest on the remaining balance of the liability. Leased assets are depreciated in accordance with the company's policy for tangible fixed assets. If there is no reasonable certainty that ownership will be obtained at the end of the lease term, the asset is depreciated over the lower of the lease term and its useful life. Operating lease payments are recognised as an expense on a straight line basis over the lease term.

2.6. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

Page 3

Page 4

Vnkpharma Ltd

Notes to the Financial Statements (continued)

For The Year Ended 30 November 2025

2.7. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.

2.8. Pensions

The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.

2.9. Debtors

Short term debtors are measured at transaction price (which is usually the invoice price), less any

impairment losses for bad and doubtful debts. Loans and other financial assets are initially

recognised at transaction price including any transaction costs and subsequently measured at

amortised cost determined using the effective interest method, less any impairment losses for

bad and doubtful debts.

2.10. Creditors

Short term creditors are measured at transaction price (which is usually the invoice price). Loans

and other financial liabilities are initially recognised at transaction price net of any transaction

costs and subsequently measured at amortised cost determined using the effective interest

method.

2.11. Provisions

Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation

at the reporting date as a result of a past event, it is probable that economic benefit will be

transferred to settle the obligation and the amount of the obligation can be estimated reliably.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 5 (2024: 5)

Page 4

Page 5

Vnkpharma Ltd

Notes to the Financial Statements (continued)

For The Year Ended 30 November 2025

4. Intangible Assets

	Goodwill
	£
Cost
As at 1 December 2024	664,997

As at 30 November 2025	664,997

Amortisation
As at 1 December 2024	113,604
Provided during the period	33,250

As at 30 November 2025	146,854

Net Book Value
As at 30 November 2025	518,143

As at 1 December 2024	551,393

5. Tangible Assets

	Land & Property
	Leasehold	Fixtures & Fittings	Total
	£	£	£
Cost
As at 1 December 2024	10,933	53,014	63,947
Additions	-	977	977

As at 30 November 2025	10,933	53,991	64,924

Depreciation
As at 1 December 2024	-	7,738	7,738
Provided during the period	-	9,087	9,087

As at 30 November 2025	-	16,825	16,825

Net Book Value
As at 30 November 2025	10,933	37,166	48,099

As at 1 December 2024	10,933	45,276	56,209

6. Debtors

	2025	2024
	£	£
Due within one year
Trade debtors	119,633	101,059
Other debtors	13,030	21,919

	132,663	122,978

Page 5

Page 6

Vnkpharma Ltd

Notes to the Financial Statements (continued)

For The Year Ended 30 November 2025

7. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Trade creditors	87,060	75,320
Corporation tax	49,154	74,641
Other creditors	238,574	331,055

	374,788	481,016

8. Related Party Transactions

Mr Neil Karia and Mrs Vanisha Patel are Directors of Vnkpharma Ltd.

As the balance sheet date, the total amount owed by the company to the directors £234,317 (2024 : £315,856).

During the year the company has declared dividend of £72,000.00 (2024: £73,000.00)

Page 6

		2025		2024
	Notes	£	£	£	£
FIXED ASSETS
Intangible Assets	4		518,143		551,393
Tangible Assets	5		48,099		56,209

			566,242		607,602
CURRENT ASSETS
Stocks		39,596		37,488
Debtors	6	132,663		122,978
Cash at bank and in hand		152,389		191,716

		324,648		352,182
Creditors: Amounts Falling Due Within One Year	7	(374,788 )		(481,016 )

NET CURRENT ASSETS (LIABILITIES)			(50,140 )		(128,834 )

TOTAL ASSETS LESS CURRENT LIABILITIES			516,102		478,768

NET ASSETS			516,102		478,768

CAPITAL AND RESERVES
Called up share capital			100		100
Profit and Loss Account			516,002		478,668

SHAREHOLDERS' FUNDS			516,102		478,768